Cargando…

Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease

The development of a progressive phenotype of interstitial lung disease (ILD) is still unpredictable. Whereas tools to predict mortality in ILD exist, scores to predict disease progression are missing. The aim of this study was to investigate whether baseline serum KL-6 as an established marker to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jehn, Lutz B., Costabel, Ulrich, Boerner, Eda, Wälscher, Julia, Theegarten, Dirk, Taube, Christian, Bonella, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917700/
https://www.ncbi.nlm.nih.gov/pubmed/36769819
http://dx.doi.org/10.3390/jcm12031173
_version_ 1784886431011831808
author Jehn, Lutz B.
Costabel, Ulrich
Boerner, Eda
Wälscher, Julia
Theegarten, Dirk
Taube, Christian
Bonella, Francesco
author_facet Jehn, Lutz B.
Costabel, Ulrich
Boerner, Eda
Wälscher, Julia
Theegarten, Dirk
Taube, Christian
Bonella, Francesco
author_sort Jehn, Lutz B.
collection PubMed
description The development of a progressive phenotype of interstitial lung disease (ILD) is still unpredictable. Whereas tools to predict mortality in ILD exist, scores to predict disease progression are missing. The aim of this study was to investigate whether baseline serum KL-6 as an established marker to assess disease activity in ILD, alone or in combination with clinical variables, could improve stratification of ILD patients according to progression risk at any time. Consecutive patients with fibrotic ILD, followed at our institution between 2008 and 2015, were investigated. Disease progression was defined as relative decline of ≥10% in forced vital capacity (FVC) or ≥15% in diffusing capacity of the lung for carbon monoxide (DLco)% from baseline at any time. Serum KL-6 was measured using an automated immunoassay (Fujirebio Europe, Gent, Belgium). A stepwise logistic regression was performed to select variables to be included in the score. A total of 205 patients (49% idiopathic pulmonary fibrosis (IPF), 51% fibrotic nonspecific interstitial pneumonia (NSIP)) were included, of them 113 (55%) developed disease progression during follow up. Male gender (G) and serum KL-6 strata (K) were significant predictors of progression at regression analysis and were included in the GK score. A threshold of 2 GK score points was best for discriminating patients at high risk versus low risk to develop disease progression at any time. Serum KL-6 concentration, alone or combined in a simple score with gender, allows an effective stratification of ILD patients for risk of disease progression at any time.
format Online
Article
Text
id pubmed-9917700
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99177002023-02-11 Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease Jehn, Lutz B. Costabel, Ulrich Boerner, Eda Wälscher, Julia Theegarten, Dirk Taube, Christian Bonella, Francesco J Clin Med Article The development of a progressive phenotype of interstitial lung disease (ILD) is still unpredictable. Whereas tools to predict mortality in ILD exist, scores to predict disease progression are missing. The aim of this study was to investigate whether baseline serum KL-6 as an established marker to assess disease activity in ILD, alone or in combination with clinical variables, could improve stratification of ILD patients according to progression risk at any time. Consecutive patients with fibrotic ILD, followed at our institution between 2008 and 2015, were investigated. Disease progression was defined as relative decline of ≥10% in forced vital capacity (FVC) or ≥15% in diffusing capacity of the lung for carbon monoxide (DLco)% from baseline at any time. Serum KL-6 was measured using an automated immunoassay (Fujirebio Europe, Gent, Belgium). A stepwise logistic regression was performed to select variables to be included in the score. A total of 205 patients (49% idiopathic pulmonary fibrosis (IPF), 51% fibrotic nonspecific interstitial pneumonia (NSIP)) were included, of them 113 (55%) developed disease progression during follow up. Male gender (G) and serum KL-6 strata (K) were significant predictors of progression at regression analysis and were included in the GK score. A threshold of 2 GK score points was best for discriminating patients at high risk versus low risk to develop disease progression at any time. Serum KL-6 concentration, alone or combined in a simple score with gender, allows an effective stratification of ILD patients for risk of disease progression at any time. MDPI 2023-02-01 /pmc/articles/PMC9917700/ /pubmed/36769819 http://dx.doi.org/10.3390/jcm12031173 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jehn, Lutz B.
Costabel, Ulrich
Boerner, Eda
Wälscher, Julia
Theegarten, Dirk
Taube, Christian
Bonella, Francesco
Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
title Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
title_full Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
title_fullStr Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
title_full_unstemmed Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
title_short Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
title_sort serum kl-6 as a biomarker of progression at any time in fibrotic interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917700/
https://www.ncbi.nlm.nih.gov/pubmed/36769819
http://dx.doi.org/10.3390/jcm12031173
work_keys_str_mv AT jehnlutzb serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease
AT costabelulrich serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease
AT boernereda serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease
AT walscherjulia serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease
AT theegartendirk serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease
AT taubechristian serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease
AT bonellafrancesco serumkl6asabiomarkerofprogressionatanytimeinfibroticinterstitiallungdisease